Tampa (Florida) [US], December 3 (ANI/PRNewswire): VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease. Concept Medical Inc. hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD Treatment: Choice of The Future' which explored the utility of Sirolimus Coated Balloon treatment in PAD. The session was chaired by Prof. Sahil Parikh, co-moderated by Prof. Edward Choke and Prof. Aloke Finn with interesting presentations by Prof. Ulf Teichgraber and Prof. Francesco Liistro. One of the highlights of the session was the follow up data of clinical outcomes of the XTOSI Trial. XTOSI (Xtreme Touch Sirolimus coated PTA balloon) is a single arm trial for Sirolimus Coated Balloon (MagicTouch PTA) investigating the clinical use and safety of the device in the treatment of infrainguinal Peripheral Arterial Disease (PAD). This prospective, premarket, non-randomized, all comers single-arm study, led by PI Prof. Edward Choke enrolled 50 patients to study the Magic Touch PTA Sirolimus Coated Balloon (Concept Medical Inc.) at Sengkang General Hospital, Singapore. It is the world's first trial of Sirolimus Coated Balloon for BTK disease and has the longest follow up data. While the primary endpoints already suggested promising patency and safety at 6 months, the data presented at VEITH 2022 shed more light on the longer-term efficacy and the safety of the Sirolimus Coated Balloon. Prof. Edward Choke, further presented updates on the FUTURE SFA and FUTURE BTK RCTs, a family of randomised trials set to enrol 279 and 219 patients respectively, against standard uncoated balloon in 2:1 fashion and are ongoing in Singapore, Taiwan and Thailand. FUTURE BTK has already completed 25% of its enrolment target, credits to the principal investigators of all sites involved. Sirolimus Coated Balloon for PAD continues its march, knocking on the doors of the US and lighting up the iconic New York Times Square with a dazzling display of the study results of XTOSI and the recruitment status of the FUTURE BTK. Watch the complete session to know more about exciting clinical data: https://youtu.be/2xokmMuhzuc This story is provided by PRNewswire. ANI will not be responsible in any way for the content of this article. (ANI/PRNewswire)
Related Keywords
New York , United States , Florida , Taiwan , Thailand , Singapore , Aloke Finn , Francesco Liistro , Ulf Teichgraber , Sahil Parikh , Concept Medical Inc , Sirolimus Coated Balloon , Edward Choke , Xtreme Touch Sirolimus , Peripheral Arterial Disease , Magic Touch , Coated Balloon , Sengkang General Hospital , Sirolimus Coated , New York Times Square , Tampa Florida Us , Ecember 3 Ani Prnewswire Veith 2022 Witnesseda Surge Of Supporting Clinical Data For Sirolimus Coated Balloon In The Treatment Below Knee Btk Disease Concept Medical Inc Hosteda Lunch Symposium Titled 39 Pad Choice Future Which Explored Utility Session Was Chaired By Prof Sahil Parikh , O Moderated By Prof Edward Choke And Aloke Finn With Interesting Presentations Ulf Teichgraber Francesco Liistro One Of The Highlights Session Was Follow Up Data Clinical Outcomes Xtosi Trial Xtreme Touch Sirolimus Coated Pta Balloon Isa Single Arm For Magictouch Investigating Use Safety Device In Treatment Infrainguinal Peripheral Arterial Disease Pad This Prospective , Premarket , On Randomized , Ll Comers Single Arm Study , Ed By Pi Prof Edward Choke Enrolled 50 Patients To Study The Magic Touch Pta Sirolimus Coated Balloon Concept Medical Inc At Sengkang General Hospital , Ingapore It Is The World 39s First Trial Of Sirolimus Coated Balloon For Btk Disease And Has Longest Follow Up Data While Primary Endpoints Already Suggested Promising Patency Safety At 6 Months , He Data Presented At Veith 2022 Shed More Light On The Longer Term Efficacy And Safety Of Sirolimus Coated Balloon Prof Edward Choke , Urther Presented Updates On The Future Sfa And Btk Rcts , A Family Of Randomised Trials Set To Enrol 279 And 219 Patients Respectively , Gainst Standard Uncoated Balloon In 2 1 Fashion And Are Ongoing Singapore , Aiwan And Thailand Future Btk Has Already Completed 25 Of Its Enrolment Target , Redits To The Principal Investigators Of All Sites Involved Sirolimus Coated Balloon For Pad Continues Its March , Nocking On The Doors Of Us And Lighting Up Iconic New York Times Square Witha Dazzling Display Study Results Xtosi Recruitment Status Future Btk Watch Complete Session To Know More About Exciting Clinical Data Https Youtu Be 2xokmmuhzuc This Story Is Provided By Prnewswire Ani Will Not Responsible In Any Way For Content Article ,
vimarsana.com © 2020. All Rights Reserved.